

Dosing and Administration Guide



INDICATIONS

DARZALEX FASPRO™ is indicated for the treatment of adult patients with multiple myeloma:

- in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant
- in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy
- in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy
- as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent

Select Important Safety Information

CONTRAINDICATIONS

DARZALEX FASPRO™ is contraindicated in patients with a history of severe hypersensitivity to daratumumab, hyaluronidase or any of the components of the formulation.

WARNINGS AND PRECAUTIONS

Warnings and Precautions include: Hypersensitivity and Other Administration Reactions, Neutropenia, Thrombocytopenia, Embryo-Fetal Toxicity, Interference with Serological Testing, and Interference with Determination of Complete Response.

Please see Important Safety Information on pages 12-18. Please [click here](#) to see the full Prescribing Information for DARZALEX FASPRO™ and [click here](#) to see the full Prescribing Information for DARZALEX®.



Content is consistent with the Oncology Nursing Society Standards and Guidelines. The Oncology Nursing Society (ONS) Seal of Approval does not constitute medical advice and does not imply product endorsement by ONS. Healthcare providers should exercise their own medical judgment. Website content or other resources referenced in these materials have not been reviewed for the Oncology Nursing Society Seal of Approval.

Janssen Biotech, Inc., has provided charitable funding to ONS previously and has also separately paid a fee for review of this material.

DARZALEX FASPRO™ benefits^{1,2}

Subcutaneous administration with DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj)



~3 to 5 minute administration by a healthcare provider



Fixed dose; no weight-based calculations



Single-dose vial, no dilution needed



Same dosing schedules as DARZALEX® (daratumumab) for approved indications*

*Split first dose option for DARZALEX® is not applicable to DARZALEX FASPRO™.



Formulated with hyaluronidase for subcutaneous administration

Select Important Safety Information

CONTRAINDICATIONS

DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) is contraindicated in patients with a history of severe hypersensitivity to daratumumab, hyaluronidase or any of the components of the formulation.

WARNINGS AND PRECAUTIONS

Hypersensitivity and Other Administration Reactions

Both systemic administration-related reactions, including severe or life-threatening reactions, and local injection-site reactions can occur with DARZALEX FASPRO™.

Systemic Reactions

In a pooled safety population of 490 patients who received DARZALEX FASPRO™ as monotherapy or in combination, 11% of patients experienced a systemic administration-related reaction (Grade 2: 3.9%, Grade 3: 1.4%). Systemic administration-related reactions occurred in 10% of patients with the first injection, 0.2% with the second injection, and cumulatively 0.8% with subsequent injections. The median time to onset was 3.7 hours (range: 9 minutes to 3.5 days). Of the 84 systemic administration-related reactions that occurred in 52 patients, 73 (87%) occurred on the day of DARZALEX FASPRO™ administration. Delayed systemic administration-related reactions have occurred in less than 1% of the patients.

~3 to 5 minute administration possible with subcutaneous formulation

DARZALEX FASPRO™ is a CD38-targeted monoclonal antibody in a subcutaneous formulation¹

DARZALEX FASPRO™ contains recombinant hyaluronidase, which is a substance that increases permeability of subcutaneous tissue, making it possible for 15 mL containing 1,800 mg of daratumumab to be administered in approximately 3 to 5 minutes.¹

Recombinant hyaluronidase works locally and transiently to degrade hyaluronan ([HA], a naturally occurring glycosaminoglycan found throughout the body) in the extracellular matrix of the subcutaneous space. It cleaves the linkage between the 2 sugars (N-acetylglucosamine and glucuronic acid) that comprise HA. Recombinant hyaluronidase has a half-life in skin of less than 30 minutes.¹

- The effects of hyaluronidase are reversible and permeability of the subcutaneous tissue is restored within 24 to 48 hours


DID YOU KNOW?

DARZALEX FASPRO™ is administered subcutaneously over ~3 to 5 minutes while DARZALEX® is given intravenously over 7 hours for the first infusion, 4 hours for Week 2, and 3 hours for subsequent infusions (median).

Select Important Safety Information (cont)

Severe reactions included hypoxia, dyspnea, hypertension and tachycardia. Other signs and symptoms of systemic administration-related reactions may include respiratory symptoms, such as bronchospasm, nasal congestion, cough, throat irritation, allergic rhinitis, and wheezing, as well as anaphylactic reaction, pyrexia, chest pain, pruritis, chills, vomiting, nausea, and hypotension. (Continued on next page)

Please see Important Safety Information on pages 12-18. Please [click here](#) to see the full Prescribing Information for DARZALEX FASPRO™ and [click here](#) to see the full Prescribing Information for DARZALEX®.

 **DARZALEX Faspro™**
(daratumumab and hyaluronidase-fihj)
Injection for subcutaneous use | 1,800mg/30,000units

~3 to 5 minute subcutaneous administration starting with the first dose

DARZALEX FASPRO™ contains 30,000 units of recombinant hyaluronidase¹

- Increases permeability of subcutaneous tissue¹
- Enables 15 mL containing 1,800 mg of daratumumab to be absorbed into the subcutaneous tissue of the abdomen¹
- Use an appropriate needle gauge. In the clinical trials, 23- to 25-gauge needles were used for the injection^{1,3}
- For subcutaneous use only. DARZALEX FASPRO™ has different dosage and administration instructions than DARZALEX® (daratumumab). Do not administer intravenously^{1,2}

Pre-medication¹

Pre-medicate patients 1 to 3 hours before each dose with a histamine-1 receptor antagonist, acetaminophen, and a corticosteroid.

~3 to 5 minute injection¹



Post-medication¹

Consider administering corticosteroids and other medications after the administration of DARZALEX FASPRO™, depending on dosing regimen and medical history to minimize the risk of delayed (defined as occurring the day after administration) systemic administration-related reactions (ARRs).*

Monitor patients for systemic ARR, especially following the first and second injections. For anaphylactic reaction or life-threatening (Grade 4) systemic ARR, immediately and permanently discontinue DARZALEX FASPRO™.

*In clinical trials of DARZALEX FASPRO™ and DARZALEX®, and in the Prescribing Information for DARZALEX®, the terms "infusion reactions" and "infusion-related reactions" were used instead of "systemic administration-related reactions."

Select Important Safety Information (cont)

Pre-medicate patients with histamine-1 receptor antagonist, acetaminophen and corticosteroids. Monitor patients for systemic administration-related reactions, especially following the first and second injections. For anaphylactic reaction or life-threatening (Grade 4) administration-related reactions, immediately and permanently discontinue DARZALEX FASPRO™. Consider administering corticosteroids and other medications after the administration of DARZALEX FASPRO™ depending on dosing regimen and medical history to minimize the risk of delayed (defined as occurring the day after administration) systemic administration-related reactions.

DARZALEX FASPRO™ dosing schedule¹

Ready-to-use, single-use vial includes a fixed dose for shorter preparation and no weight-based calculations

Indicated regimen*	Weeks	Schedule
In combination with lenalidomide (REVLIMID®) (4-week cycle) and dexamethasone, or for monotherapy	1–8	Weekly (total of 8 doses)
	9–24	Every 2 weeks (total of 8 doses)
	25 onward until disease progression	Every 4 weeks
With bortezomib (VELCADE®), melphalan, and prednisone (6-week cycle)	1–6	Weekly (total of 6 doses)
	7–54	Every 3 weeks (total of 16 doses)
	55 onward until disease progression	Every 4 weeks
With bortezomib and dexamethasone (3-week cycle)	1–9	Weekly (total of 9 doses)
	10–24	Every 3 weeks (total of 5 doses)
	25 onward until disease progression	Every 4 weeks

*See dosage and administration section of the full Prescribing Information for more detail. When DARZALEX FASPRO™ is administered as part of a combination therapy, see the prescribing information for dosage recommendations for the other drugs.

Select Important Safety Information (cont)

Local Reactions


In this pooled safety population, injection-site reactions occurred in 8% of patients, including Grade 2 reactions in 0.6%. The most frequent (>1%) injection-site reaction was injection site erythema. These local reactions occurred a median of 7 minutes (range: 0 minutes to 4.7 days) after starting administration of DARZALEX FASPRO™. Monitor for local reactions and consider symptomatic management.

Please see Important Safety Information on pages 12-18. Please [click here](#) to see the full Prescribing Information for DARZALEX FASPRO™ and [click here](#) to see the full Prescribing Information for DARZALEX®.

DARZALEX Faspro™
(daratumumab and hyaluronidase-fihj)
Injection for subcutaneous use | 1,800mg/30,000units

Preparation

Before you begin, collect your supplies^{3*}



STEP 1: Inspect and prepare the vial¹

- Remove the DARZALEX FASPRO™ vial from the refrigerator and warm to room temperature. Check the liquid in the vial. Keep out of direct sunlight and do not shake
- To prevent medication errors, it is important to check the vial labels to ensure that the drug being prepared and administered is DARZALEX FASPRO™ for subcutaneous injection and not DARZALEX® (daratumumab)
- DARZALEX FASPRO™ subcutaneous formulation is not intended for intravenous administration and should be administered via subcutaneous injection only
- Label the syringe appropriately to include the route of administration per institutional standards
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if opaque particles, discoloration or other foreign particles are present



DID YOU KNOW?

If you prefer, you may use a winged infusion set to administer DARZALEX FASPRO™.³

Select Important Safety Information (cont)

Neutropenia

Daratumumab may increase neutropenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. Consider withholding DARZALEX FASPRO™ until recovery of neutrophils. In lower body weight patients receiving DARZALEX FASPRO™, higher rates of Grade 3-4 neutropenia were observed.

STEP 2: Attach the transfer needle and fill the syringe¹


Prepare the dosing syringe in controlled and validated aseptic conditions.

- Using the transfer needle, withdraw the full content of the vial into a 20 mL dosing syringe
- To avoid clogging, attach the needle to the syringe immediately prior to injection




STEP 3: Attach the injection needle and set the dose³

- Remove the transfer needle and attach the injection needle to the syringe
- Prime the syringe and set the dose to 15 mL



STEP 4: Choose and prepare the injection site on the abdomen^{1,3}

- Do not inject into skin on the abdomen that is tender, bruised, red, hard or has scars
- Wipe your chosen injection site with an alcohol swab and allow it to dry
- Rotate injection sites for each successive injection



NEED TO KNOW

To prevent medication errors, it is important to check the vial labels to ensure that the drug being prepared and administered is DARZALEX FASPRO™ and not DARZALEX®.¹

Select Important Safety Information (cont)

Thrombocytopenia

Daratumumab may increase thrombocytopenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Consider withholding DARZALEX FASPRO™ until recovery of platelets.

Please see Important Safety Information on pages 12-18. Please [click here](#) to see the full Prescribing Information for DARZALEX FASPRO™ and [click here](#) to see the full Prescribing Information for DARZALEX®.

DARZALEX Faspro™
(daratumumab and hyaluronidase-fihj)
Injection for subcutaneous use | 1,800mg/30,000units

Administration

DARZALEX FASPRO™ makes subcutaneous administration possible starting with the first dose

DARZALEX FASPRO™ is for single use only and comes in a ready-to-use vial

STEP 1: Insert needle at a 45-degree angle³

When you and your patient are comfortable, start the injection.

- Pinch skin at the injection site on the abdomen. It is important to pinch enough skin to inject under the skin and not into the muscle
- Insert needle with a quick, dart-like motion
- Try to limit needle and syringe movement during the injection. If needed, secure the infusion set in place with a bandage

STEP 2: Inject the dose¹

- Inject 15 mL DARZALEX FASPRO™ into the subcutaneous tissue of the abdomen approximately 3 inches (7.5 cm) to the right or left of the navel
- Press the plunger with a constant rate of administration for approximately 3 to 5 minutes
- If the patient feels pain, pause or slow down the rate of administration. If the patient still feels pain, consider using a different injection site on the opposite side of the abdomen to deliver the remainder of the dose
- Do not inject DARZALEX FASPRO™ at other sites of the body as no data are available
- Injection sites should be rotated for successive injections
- Do not administer other medications for subcutaneous use at the same site
- DARZALEX FASPRO™ subcutaneous formulation should never be injected into areas where the skin is red, bruised, tender, hard or areas where there are scars



Select Important Safety Information (cont)

Embryo-Fetal Toxicity

Based on the mechanism of action, DARZALEX FASPRO™ can cause fetal harm when administered to a pregnant woman. DARZALEX FASPRO™ may cause depletion of fetal immune cells and decreased bone density. Advise pregnant women of the potential risk to a fetus. Advise females with reproductive potential to use effective contraception during treatment with DARZALEX FASPRO™ and for 3 months after the last dose.

Handling and storage¹

Prior to administration, remove DARZALEX FASPRO™ from refrigerated storage (2°C–8°C [36°F–46°F]) and equilibrate to ambient temperature (15°C–30°C [59°F–86°F]). The unpunctured vial may be stored at ambient temperature and ambient light for a maximum of 24 hours. Keep out of direct sunlight. Do not shake.

Liquid product (120 mg/mL) comes in a single-use, sterile vial; inspect the vial contents and expiration.

If the syringe containing DARZALEX FASPRO™ is not used immediately, the DARZALEX FASPRO™ solution (in syringe) can be kept for up to 4 hours at ambient temperature and ambient light.

Select Important Safety Information (cont)

The combination of DARZALEX FASPRO™ with lenalidomide is contraindicated in pregnant women, because lenalidomide may cause birth defects and death of the unborn child. Refer to the lenalidomide prescribing information on use during pregnancy.

Interference with Serological Testing


Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive Indirect Antiglobulin Test (Indirect Coombs test). Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab administration. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient's serum. The determination of a patient's ABO and Rh blood type are not impacted.

Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX FASPRO™. Type and screen patients prior to starting DARZALEX FASPRO™.

Interference with Determination of Complete Response


Daratumumab is a human IgG kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and of disease progression in some DARZALEX FASPRO™-treated patients with IgG kappa myeloma protein.

Please see Important Safety Information on pages 12-18. Please [click here](#) to see the full Prescribing Information for DARZALEX FASPRO™ and [click here](#) to see the full Prescribing Information for DARZALEX®.

 **DARZALEX Faspro™**
(daratumumab and hyaluronidase-fihj)
Injection for subcutaneous use | 1,800mg/30,000units

Fewer systemic administration-related reactions (ARRs)

Nearly **3x reduction in systemic ARR**s with DARZALEX FASPRO™ vs DARZALEX® (daratumumab) observed in the COLUMBA trial¹



Both systemic ARRs, including severe or life-threatening reactions, and local injection-site reactions can occur with DARZALEX FASPRO™.¹

In a pooled safety population of 490 patients, the rate of systemic ARRs was 11% for DARZALEX FASPRO™¹

- The median time to onset of systemic ARRs following an injection of DARZALEX FASPRO™ was 3.7 hours (range: 9 minutes to 3.5 days). The majority of systemic ARRs occurred on the day of treatment. Delayed systemic ARRs, those occurring after the day of administration, have occurred in less than 1% of patients
- The incidence of any grade systemic ARRs was 10% with the first injection of DARZALEX FASPRO™ at Week 1, 0.2% with the second injection at Week 2, and cumulatively 0.8% with subsequent injections

Local reactions¹

- In this pooled safety population, injection-site reactions occurred in 8% of patients, including Grade 2 reactions in 0.6%. The most frequent (>1%) injection-site reaction was injection site erythema
- These local reactions occurred a median of 7 minutes (range: 0 minutes to 4.7 days) after starting administration of DARZALEX FASPRO™. Monitor for local reactions and consider symptomatic management

¹Systemic ARRs causing severe reactions included hypoxia, dyspnea, hypertension, and tachycardia. Other signs and symptoms of systemic ARRs may include respiratory symptoms, such as bronchospasm, nasal congestion, cough, throat irritation, allergic rhinitis, and wheezing, as well as anaphylactic reaction, pyrexia, chest pain, pruritus, chills, vomiting, nausea, and hypotension.¹



The most common adverse reactions with combination therapy (≥20% for any combination) include fatigue, nausea, diarrhea, dyspnea, insomnia, pyrexia, cough, muscle spasms, back pain, vomiting, upper respiratory tract infection, peripheral sensory neuropathy, constipation, and pneumonia¹

Safety generally consistent with DARZALEX®

Adverse reactions reported in ≥10% of patients and select laboratory abnormalities worsening from baseline in patients receiving either DARZALEX FASPRO™ or DARZALEX®¹

Adverse reactions	DARZALEX FASPRO™ (n=260)		DARZALEX® (n=258)	
	All grades (%)	Grade ≥3 (%)	All grades (%)	Grade ≥3 (%)
Upper respiratory tract infection ^a	24	1 ^a	22	1 ^a
Pneumonia ^b	8	5	10	6 ^h
Diarrhea	15	1 ^a	11	0.4 ^a
Nausea	8	0.4 ^a	11	0.4 ^a
Fatigue ^c	15	1 ^a	16	2 ^a
Systemic ARRs ^d	13	2 ^a	34	5 ^a
Pyrexia	13	0	13	1 ^a
Chills	6	0.4 ^a	12	1 ^a
Back pain	10	2 ^a	12	3 ^a
Cough ^e	9	1 ^a	14	0
Dyspnea ^f	6	1 ^a	11	1 ^a

^aUpper respiratory tract infection includes acute sinusitis, nasopharyngitis, pharyngitis, respiratory syncytial virus infection, respiratory tract infection, rhinitis, rhinovirus infection, sinusitis, and upper respiratory tract infection.

^bPneumonia includes lower respiratory tract infection, lung infection, pneumocystis jirovecii pneumonia, and pneumonia.

^cFatigue includes asthenia and fatigue.

^dSystemic ARRs includes terms determined by investigators to be related to infusion. In clinical trials of DARZALEX FASPRO™, DARZALEX®, and the Prescribing Information for DARZALEX®, the term "infusion reactions" was used instead of "systemic ARRs."

^eCough includes cough and productive cough.

^fDyspnea includes dyspnea and dyspnea exertional.

^gOnly Grade 3 adverse reactions occurred.

^hGrade 5 adverse reactions occurred.

- Serious adverse reactions occurred in 26% of patients who received DARZALEX FASPRO™ vs 29% who received DARZALEX®. Fatal adverse reactions occurred in 5% of patients receiving DARZALEX FASPRO™. Fatal adverse reactions occurring in more than 1 patient were general physical health deterioration, septic shock, and respiratory failure. Fatal adverse reactions occurred in 7% of patients receiving DARZALEX®.^{1,4}

Laboratory abnormalities	DARZALEX FASPRO™ (n=260) ^a		DARZALEX® (n=258) ^a	
	All grades (%)	Grade 3-4 (%)	All grades (%)	Grade 3-4 (%)
Decreased leukocytes	65	19	57	14
Decreased lymphocytes	59	36	56	36
Decreased neutrophils	55	19	43	11
Decreased platelets	43	16	45	14
Decreased hemoglobin	42	14	39	16

^aDenominator is based on the safety population treated with DARZALEX FASPRO™ (n=260) or with DARZALEX® (n=258).

Please see Important Safety Information on pages 12-18. Please [click here](#) to see the full Prescribing Information for DARZALEX FASPRO™ and [click here](#) to see the full Prescribing Information for DARZALEX®.

DARZALEX Faspro™
(daratumumab and hyaluronidase-fihj)
Injection for subcutaneous use | 1,800mg/30,000units

Important Safety Information for DARZALEX FASPRO™

CONTRAINDICATIONS

DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) is contraindicated in patients with a history of severe hypersensitivity to daratumumab, hyaluronidase or any of the components of the formulation.

WARNINGS AND PRECAUTIONS

Hypersensitivity and Other Administration Reactions

Both systemic administration-related reactions, including severe or life-threatening reactions, and local injection-site reactions can occur with DARZALEX FASPRO™.

Systemic Reactions

In a pooled safety population of 490 patients who received DARZALEX FASPRO™ as monotherapy or in combination, 11% of patients experienced a systemic administration-related reaction (Grade 2: 3.9%, Grade 3: 1.4%). Systemic administration-related reactions occurred in 10% of patients with the first injection, 0.2% with the second injection, and cumulatively 0.8% with subsequent injections. The median time to onset was 3.7 hours (range: 9 minutes to 3.5 days). Of the 84 systemic administration-related reactions that occurred in 52 patients, 73 (87%) occurred on the day of DARZALEX FASPRO™ administration. Delayed systemic administration-related reactions have occurred in less than 1% of the patients.

Severe reactions included hypoxia, dyspnea, hypertension and tachycardia. Other signs and symptoms of systemic administration-related reactions may include respiratory symptoms, such as bronchospasm, nasal congestion, cough, throat irritation, allergic rhinitis, and wheezing, as well as anaphylactic reaction, pyrexia, chest pain, pruritis, chills, vomiting, nausea, and hypotension.

Pre-medicate patients with histamine-1 receptor antagonist, acetaminophen and corticosteroids. Monitor patients for systemic administration-related reactions, especially following the first and second injections. For anaphylactic reaction or life-threatening (Grade 4) administration-related reactions, immediately and permanently discontinue DARZALEX FASPRO™. Consider administering corticosteroids and other medications after the administration of DARZALEX FASPRO™ depending on dosing regimen and medical history to minimize the risk of delayed (defined as occurring the day after administration) systemic administration-related reactions.

Local Reactions

In this pooled safety population, injection-site reactions occurred in 8% of patients, including Grade 2 reactions in 0.6%. The most frequent (>1%) injection-site reaction was injection site erythema. These local reactions occurred a median of 7 minutes (range: 0 minutes to 4.7 days) after starting administration of DARZALEX FASPRO™. Monitor for local reactions and consider symptomatic management.

Neutropenia

Daratumumab may increase neutropenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. Consider withholding DARZALEX FASPRO™ until recovery of neutrophils. In lower body weight patients receiving DARZALEX FASPRO™, higher rates of Grade 3-4 neutropenia were observed.

Thrombocytopenia

Daratumumab may increase thrombocytopenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Consider withholding DARZALEX FASPRO™ until recovery of platelets.

Embryo-Fetal Toxicity

Based on the mechanism of action, DARZALEX FASPRO™ can cause fetal harm when administered to a pregnant woman. DARZALEX FASPRO™ may cause depletion of fetal immune cells and decreased bone density. Advise pregnant women of the potential risk to a fetus. Advise females with reproductive potential to use effective contraception during treatment with DARZALEX FASPRO™ and for 3 months after the last dose.

The combination of DARZALEX FASPRO™ with lenalidomide is contraindicated in pregnant women, because lenalidomide may cause birth defects and death of the unborn child. Refer to the lenalidomide prescribing information on use during pregnancy.

Continued on next page

Important Safety Information for DARZALEX FASPRO™ (cont)

Interference with Serological Testing

Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive Indirect Antiglobulin Test (Indirect Coombs test). Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab administration. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient's serum. The determination of a patient's ABO and Rh blood type are not impacted.

Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX FASPRO™. Type and screen patients prior to starting DARZALEX FASPRO™.

Interference with Determination of Complete Response

Daratumumab is a human IgG kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and of disease progression in some DARZALEX FASPRO™-treated patients with IgG kappa myeloma protein.

ADVERSE REACTIONS

The most common adverse reaction (≥20%) with DARZALEX FASPRO™ monotherapy is: upper respiratory tract infection. The most common adverse reactions with combination therapy (≥20% for any combination) include fatigue, nausea, diarrhea, dyspnea, insomnia, pyrexia, cough, muscle spasms, back pain, vomiting, upper respiratory tract infection, peripheral sensory neuropathy, constipation, and pneumonia.

The most common hematology laboratory abnormalities (≥40%) with DARZALEX FASPRO™ are: decreased leukocytes, decreased lymphocytes, decreased neutrophils, decreased platelets, and decreased hemoglobin.

Please [click here](#) to see the full Prescribing Information.

cp-143279v1

Indications and Important Safety Information for DARZALEX®

INDICATIONS

DARZALEX® (daratumumab) is indicated for the treatment of adult patients with multiple myeloma:

- In combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy
- In combination with bortezomib, melphalan, and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant
- In combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant
- In combination with bortezomib and dexamethasone in patients who have received at least one prior therapy
- In combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy
- In combination with pomalidomide and dexamethasone in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor
- As monotherapy in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

DARZALEX® is contraindicated in patients with a history of severe hypersensitivity (eg, anaphylactic reactions) to daratumumab or any of the components of the formulation.

Continued on next page

Important Safety Information for DARZALEX® (cont)

WARNINGS AND PRECAUTIONS

Infusion-Related Reactions

DARZALEX® can cause severe and/or serious infusion-related reactions including anaphylactic reactions. In clinical trials (monotherapy and combination: N=2066), infusion-related reactions occurred in 37% of patients with the Week 1 (16 mg/kg) infusion, 2% with the Week 2 infusion, and cumulatively 6% with subsequent infusions. Less than 1% of patients had a Grade 3/4 infusion-related reaction at Week 2 or subsequent infusions. The median time to onset was 1.5 hours (range: 0 to 73 hours). Nearly all reactions occurred during infusion or within 4 hours of completing DARZALEX®. Severe reactions have occurred, including bronchospasm, hypoxia, dyspnea, hypertension, laryngeal edema, and pulmonary edema. Signs and symptoms may include respiratory symptoms, such as nasal congestion, cough, throat irritation, as well as chills, vomiting, and nausea. Less common symptoms were wheezing, allergic rhinitis, pyrexia, chest discomfort, pruritus, and hypotension.

When DARZALEX® dosing was interrupted in the setting of ASCT (CASSIOPEIA) for a median of 3.75 months (range: 2.4 to 6.9 months), upon re-initiation of DARZALEX®, the incidence of infusion-related reactions was 11% for the first infusion following ASCT. Infusion-related reactions occurring at re-initiation of DARZALEX® following ASCT were consistent in terms of symptoms and severity (Grade 3 or 4: <1%) with those reported in previous studies at Week 2 or subsequent infusions. In EQUULEUS, patients receiving combination treatment (n=97) were administered the first 16 mg/kg dose at Week 1 split over two days, ie, 8 mg/kg on Day 1 and Day 2, respectively. The incidence of any grade infusion-related reactions was 42%, with 36% of patients experiencing infusion-related reactions on Day 1 of Week 1, 4% on Day 2 of Week 1, and 8% with subsequent infusions.

Pre-medicate patients with antihistamines, antipyretics, and corticosteroids. Frequently monitor patients during the entire infusion. Interrupt DARZALEX® infusion for reactions of any severity and institute medical management as needed. Permanently discontinue DARZALEX® therapy if an anaphylactic reaction or life-threatening (Grade 4) reaction occurs and institute appropriate emergency care. For patients with Grade 1, 2, or 3 reactions, reduce the infusion rate when re-starting the infusion.

To reduce the risk of delayed infusion-related reactions, administer oral corticosteroids to all patients following DARZALEX® infusions. Patients with a history of chronic obstructive pulmonary disease may require additional post-infusion medications to manage respiratory complications. Consider prescribing short- and long-acting bronchodilators and inhaled corticosteroids for patients with chronic obstructive pulmonary disease.

Interference With Serological Testing

Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive Indirect Antiglobulin Test (Indirect Coombs test). Daratumumab-mediated positive Indirect Antiglobulin Test may persist for up to 6 months after the last daratumumab infusion. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient's serum. The determination of a patient's ABO and Rh blood type is not impacted. Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX®. Type and screen patients prior to starting DARZALEX®.

Neutropenia and Thrombocytopenia

DARZALEX® may increase neutropenia and thrombocytopenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. Consider withholding DARZALEX® until recovery of neutrophils or for recovery of platelets.

Interference With Determination of Complete Response

Daratumumab is a human IgG kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and of disease progression in some patients with IgG kappa myeloma protein.

Embryo-Fetal Toxicity

Based on the mechanism of action, DARZALEX® can cause fetal harm when administered to a pregnant woman. DARZALEX® may cause depletion of fetal immune cells and decreased bone density. Advise pregnant women of the potential risk to a fetus. Advise females with reproductive potential to use effective contraception during treatment with DARZALEX® and for 3 months after the last dose.

The combination of DARZALEX® with lenalidomide, pomalidomide, or thalidomide is contraindicated in pregnant women, because lenalidomide, pomalidomide, and thalidomide may cause birth defects and death of the unborn child. Refer to the lenalidomide, pomalidomide, or thalidomide prescribing information on use during pregnancy.

Continued on next page

 **DARZALEX®**
(daratumumab)
injection for intravenous infusion
100 mg/5 mL, 400 mg/20 mL

Important Safety Information for DARZALEX® (cont)

ADVERSE REACTIONS

The most frequently reported adverse reactions (incidence $\geq 20\%$) were: upper respiratory infection, neutropenia, infusion-related reactions, thrombocytopenia, diarrhea, constipation, anemia, peripheral sensory neuropathy, fatigue, peripheral edema, nausea, cough, pyrexia, dyspnea, and asthenia. The most common hematologic laboratory abnormalities ($\geq 40\%$) with DARZALEX® are: neutropenia, lymphopenia, thrombocytopenia, leukopenia, and anemia.

Please [click here](#) to see the full Prescribing Information.

cp-60862v6

Janssen
CarePath

We can help make it simple for you to help your patients

Janssen CarePath is your one source for access, affordability, and treatment support for your patients

Janssen CarePath helps verify insurance coverage for your patients, provides reimbursement information, helps find financial assistance options for eligible patients, and provides ongoing support to help patients start and stay on DARZALEX FASPRO™.



Call a **Janssen CarePath** Care Coordinator at **877-CarePath (877-227-3728)**, Monday–Friday, 8:00 AM to 8:00 PM ET



Sign Up or Log In to the Provider Portal at [JanssenCarePathPortal.com](https://www.JanssenCarePathPortal.com)




Visit www.janssencarepath.com/hcp/darzalex-faspro

To contact Janssen Medical Information, call **1-800-Janssen (1-800-526-7736)**.

E-mail:

Submit questions via www.askjanssenmedinfo.com

Search: www.JanssenMD.com

 **DARZALEX Faspro™**
(daratumumab and hyaluronidase-fihj)
Injection for subcutaneous use | 1,800mg/30,000units

DARZALEX FASPRO™ – a subcutaneous formulation for use across 5 indications spanning a wide range of multiple myeloma patients¹

Five approved indications

- Multiple regimens approved across a wide range of patients, including DRd and DVMP for patients who are newly diagnosed and transplant ineligible, DRd and DVd after ≥1 prior therapy, and monotherapy after ≥3 prior lines of therapy^{1*}

*Including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.

Faster administration

- ~3–5 minute injection is substantially faster than DARZALEX® (daratumumab)^{1,2}

Dosing features

- Ready-to-use, fixed-dose vial, with no weight-based calculations required¹
- Same dosing schedules as DARZALEX® for approved indications^{1,2†}

†Split first dose option for DARZALEX® is not applicable to DARZALEX FASPRO™.

Fewer systemic administration-related reactions (ARRs)

- Nearly 3x reduction in systemic ARRs vs DARZALEX® (13% vs 34%)^{1,4}
- Both systemic ARRs, including severe or life-threatening reactions, and local injection-site reactions can occur with DARZALEX FASPRO™. See Important Safety Information on pages 12-14 for more details¹

DRd=DARZALEX FASPRO™ (D) + lenalidomide (R) + dexamethasone (d); DVd=DARZALEX FASPRO™ (D) + bortezomib (V) + dexamethasone (d); DVMP=DARZALEX FASPRO™ (D) + bortezomib (V) + melphalan (M) + prednisone (P).

Select Important Safety Information (cont)

CONTRAINDICATIONS

DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) is contraindicated in patients with a history of severe hypersensitivity to daratumumab, hyaluronidase or any of the components of the formulation.

WARNINGS AND PRECAUTIONS

Warnings and Precautions include: Hypersensitivity and Other Administration Reactions, Neutropenia, Thrombocytopenia, Embryo-Fetal Toxicity, Interference with Serological Testing, and Interference with Determination of Complete Response.

Please see Important Safety Information on pages 12-18. Please [click here](#) to see the full Prescribing Information for DARZALEX FASPRO™ and [click here](#) to see the full Prescribing Information for DARZALEX®.

References: 1. DARZALEX FASPRO™ [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. DARZALEX® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 3. Data on file. Janssen Biotech, Inc. 4. Mateos M-V, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. *Lancet Haematol.* 2020;7(5):e370-e380.

Trademarks are the property of their respective owners.